Heliyon (Aug 2021)

Camptothecin shows better promise than Curcumin in the inhibition of the Human Telomerase: A computational study

  • Adekunle Babajide Rowaiye,
  • Yoroshi Joana Teca Mendes,
  • Samson Ayodeji Olofinsae,
  • John Breakthrough Oche,
  • Oluwakemi Hannah Oladipo,
  • Okiemute Ajiroghene Okpalefe,
  • Joyce Oloaigbe Ogidigo

Journal volume & issue
Vol. 7, no. 8
p. e07742

Abstract

Read online

Objectives: The Human Telomerase enzyme has become a drug target in the treatment of cancers and age-related disorders. This study aims to identify potential natural inhibitors of the Human Telomerase from compounds derived from edible African plants. Materials and methods: A library of 1,126 natural compounds was molecularly docked against the Telomerase Reverse Transcriptase (PDB ID: 5ugw), the catalytic subunit of the target protein. Curcumin, a known Telomerase inhibitor was used as the standard. The front-runner compounds were screened for bioavailability, pharmacokinetic properties, and bioactivity using the SWISSADME, PKCSM, and Molinspiration webservers respectively. The molecular dynamic simulation and analyses of the apo and holo proteins were performed by the Galaxy supercomputing webserver. Results: The results of the molecular docking and virtual screening reveal Augustamine and Camptothecin as lead compounds. Augustamine has better drug-likeness and pharmacokinetic properties while Camptothecin showed better bioactivity and stronger binding affinity (-8.2 kcal/mol) with the target. The holo structure formed by Camptothecin showed greater inhibitory activity against the target with a total RMSF of 169.853, B-Factor of 20.164, and 108 anti-correlating residues. Conclusion: Though they both act at the same binding site, Camptothecin induces greater Telomerase inhibition and better molecular stability than the standard, Curcumin. Further tests are required to investigate the inhibitory activities of the lead compounds.

Keywords